Modern approaches to diagnostics of hyperandrogenism distributed forms in reproductive aged women




insulin resistance, abdominal obesity, impaired glucose tolerance, hyperglycemia, proinsulin, hyperandrogenism


PCOS is a widespread endocrine disorder of polymorphic ethiology and pathogenesis and varying phenotypic forms that has negative effect non only on reproductive function but also on glucose and lipid metabolism, cardiovascular health, psychological wellbeing and oncologic risks throughout all life of women and their offsprings.

Diagnosis of PCOS is based upon at least 2 of the 3 criteria: clinical/biochemical hyperandrogenism, olygo-anovulation, polycystic ovarian morphotype on ultrasound. Exclusion of all other causes of hyperandogenism and anovulation is mandatory.

PCOS women both with and without obesity or overweight have significantly higher risk of glucose metabolism disorders and dyslipidemia starting from reproductive age, which leads to diabetes mellitus and cardiovascular disease in older age.

Interconnected processes of hyperandrogenism and insulin resistance are the main causes of high risks of cardiometabolic complications in women with PCOS.

At the same time PCOS is among risk factors of DM2 which makes screening of all women with PCOS for disglycemia irrespectable of BMI reasonable.

Evaluation of insulin resistance in PCOS in clinical setting may be complicated.

Contemporary laboratory tests make diagnosis of all stages of dysglicemia from insulin resistance to diabetes possible as well as monitoring of applied interventions (lifestyle modification, medications).

Thus, contemporary management of PCOS implies not only correction of reproductive disorders but also prevention of metabolic risks and comorbidities lifelong starting from the moment PCOS is diagnosed.

Author Biographies

О. А. Бурка, A.A. Bogomolets National Medical University; Medical Laboratory “DILA”

PhD, associate professor of the Obstetrics and Gynecology Department No. 1;

scientific consultant

М. І. Бобрик, A.A. Bogomolets National Medical University; Medical Laboratory “DILA”

PhD, assosiate professor at the Endocrynology Department;

scientific consultant

В. М. Резниченко, SI “Polyclinic № 2” of the State Management of Affairs

Endocrinologist high category

Т. М. Тутченко, SI “O.M. Lukyanova IPOG of the NAMS of Ukraine”; Medical Laboratory “DILA”

PhD, researcher of the Endocrine Gynecology Department;

scientific consultant


  1. Rocha, A.L., Oliveira, F.R., Azevedo, R.C., et al. “Recent advances in the understanding and management of polycystic ovary syndrome. F1000Research 8 (2019): 565.
  2. Fauser, B.C.J.M., Tarlatzis, B.C., Rebar, R.W., et al. “Consensus on women’s health aspects of polycystic ovary syndrome
  3. (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group.” Fertil Steril 97.1 (2012): 28–38.e25.
  4. Kakoly, N.S., Khomami, M.B., Joham, A.E., et al. “Ethnicity, obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in PCOS: a systematic review and meta-regression.” Hum Reprod Update 24.4 (2018): 455–67.
  5. Wild, R.A., Rizzo, M., Clifton, S., Carmina, E. “Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis.” Fertil Steril 95.3 (2011): 1073–1079.e11.
  6. Schmidt, J., Landin-Wilhelmsen, K., Brännström, M., Dahlgren, E. “Cardiovascular Disease and Risk Factors in PCOS Women of Postmenopausal Age: A 21-Year Controlled Follow-Up Study.” J Clin Endocrinol Metab 96.12 (2011): 3794–803.
  7. Behboudi-Gandevani, S., Ramezani Tehrani, F., Hosseinpanah, F., et al. “Cardiometabolic risks in polycystic ovary syndrome: long-term population-based follow-up study.” Fertil Steril 110.7 (2018): 1377–86.
  8. Yu, H.-F., Chen, H.-S., Rao, D.-P., Gong, J. “Association between polycystic ovary syndrome and the risk of pregnancy complications: A PRISMA-compliant systematic review and meta-analysis.” Medicine (Baltimore) 95.51 (2016): e4863.
  9. Kahal, H., Kyrou, I., Tahrani, A.A., Randeva, H.S. “Obstructive sleep apnoea and polycystic ovary syndrome: A comprehensive review of clinical interactions and underlying pathophysiology.” Clin Endocrinol (Oxf) 87.4 (2017): 313–9.
  10. Cooney, L.G., Lee, I., Sammel, M.D., Dokras, A. “High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: a systematic review and meta-analysis.” Hum Reprod 32.5 (2017): 1075–91.
  11. Barry, J., Azizia, M. “Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis.” Update PH-H reproduction (2014). Available from: [https://academic.], last accessed May 16, 2019.
  12. Rocha, A.L.L., Faria, L.C., Guimarães, T.C.M., et al. “Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis.” J Endocrinol Invest 40.12 (2017): 1279–88.
  13. Cooney, L. “Beyond fertility: polycystic ovary syndrome and long-term health.” Elsevier (2018). Available from: [], last accessed May 16, 2019.
  14. Romitti, M., Fabris, V.C., Ziegelmann, P.K., et al. “Association between PCOS and autoimmune thyroid disease: a systematic review and meta-analysis.” Endocr Connect 7.11 (2018): 1158–67.
  15. Shi, X.-Y., Huang, A.-P., Xie, D.-W., Yu, X.-L. “Association of vitamin D receptor gene variants with polycystic ovary syndrome: a meta-analysis.” BMC Med Genet 20.1 (2019): 32.
  16. He, C., Lin, Z., Robb, S., et al. “Serum Vitamin D Levels and Polycystic Ovary syndrome: A Systematic Review and Meta-Analysis.” Nutrients 7.6 (2015): 4555–77.
  17. American Diabetes Association. “Standards of Medical Care in Diabetes-2018 Abridged for Primary Care Providers.” Clin Diabetes 36.1 (2018): 14–37.
  18. Teede, H.J., Misso, M.L., Costello, M.F., et al. “Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.” Hum Reprod 33.9 (2018): 1602–18.
  19. Moran, L.J., Misso, M.L., Wild, R.A., Norman, R.J. “Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis.” Hum Reprod Update 16.4 (2010): 347–63.
  20. Stepto, N.K., Cassar, S., Joham, A.E., et al. “Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp.” Hum Reprod 28.3 (2013): 777–84.
  21. Cassar, S., Misso, M.L., Hopkins, W.G., et al. “Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies.” Hum Reprod 31.11 (2016): 2619–31.
  22. Anagnostis, P., Tarlatzis, B.C., Kauffman, R.P. “Polycystic ovarian syndrome (PCOS): Long-term metabolic consequences.” Metabolism 86 (2018): 33–43.
  23. Diamanti-Kandarakis, E., Panidis, D. “Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): a prospective study of 634 women with PCOS.” Clin Endocrinol (Oxf) 67.5 (2007): 735–42.
  24. Engmann, L., Jin, S., Sun, F., et al. “Racial and ethnic differences in the polycystic ovary syndrome metabolic phenotype.” Am J Obstet Gynecol 216.5 (2017): 493.e1–493. e13.
  25. Zhao, Y., Fu, L., Li, R., et al. “Metabolic profiles characterizing different phenotypes of polycystic ovary syndrome: plasma metabolomics analysis.” BMC Med 10 (2012): 153.
  26. Samuel, V.T., Shulman, G.I. “The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux.” J Clin Invest 126.1 (2016): 12–22.
  27. NCEP Adult Treatment Panel III. “Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.” Circulation 106.25 (2002): 3143–421.
  28. Glintborg, D., Rubin, K.H., Nybo, M., et al. “Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome.” Cardiovasc Diabetol 17.1 (2018): 37.
  29. Chan, D.C., Watts, G.F. “Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies.” Expert Opin Pharmacother 12.1 (2011): 13–30.
  30. Goodman, N.F., Cobin, R.H., Futterweit, W., et al. “American Association of Clinical Endocrinologists, American College Of Endocrinology, and Androgen Excess and PCOS Society Disease State clinical review: Guide to the best practices in the evaluation and treatment of polycystic ovary syndrome - Part 1.” Endocr Pract 21.11 (2015): 1291–300.
  31. Meyer, C., McGrath, B.P., Cameron, J., et al. “Vascular Dysfunction and Metabolic Parameters in Polycystic Ovary Syndrome.” J Clin Endocrinol Metab 90.8 (2005): 4630–5.
  32. Zimmermann, S., Phillips, R.A., Dunaif, A., et al. “Polycystic ovary syndrome: lack of hypertension despite profound insulin resistance.” J Clin Endocrinol Metab 75.2 (1992): 508–13.
  33. Elting, M.W., Korsen, T.J., Bezemer, P.D., Schoemaker, J. “Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population.” Hum Reprod 16.3 (2001): 556–60.
  34. Chen, M.-J., Yang, W.-S., Yang, J.-H., et al. “Relationship Between Androgen Levels and Blood Pressure in Young Women With Polycystic Ovary Syndrome.” Hypertension 49.6 (2007): 1442–7.
  35. Holte, J., Gennarelli, G., Berne, C., et al. “Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state?” Hum Reprod 11.1 (1996): 23–8.
  36. Moretti, C., Lanzolla, G., Moretti, M., et al. “Androgens and Hypertension in Men and Women: a Unifying View.” Curr Hypertens Rep 19.5 (2017): 44.
  37. Wenner, M.M., Taylor, H.S., Stachenfeld, N.S. “Androgens influence microvascular dilation in PCOS through ET-A and ET-B receptors.” Am J Physiol Metab 305.7 (2013): E818–25.
  38. Wenner, M.M., Taylor, H.S., Stachenfeld, N.S. “Endothelin B receptor contribution to peripheral microvascular function in women with polycystic ovary syndrome.” J Physiol. 589 Pt 19 (2011): 4671–9.
  39. Gilbert, E.W., Tay, C.T., Hiam, D.S., et al. “Comorbidities and complications of polycystic ovary syndrome: An overview of systematic reviews.” Clin Endocrinol (Oxf) 89.6 (2018): 683–99.
  40. Khatibi, A., Agardh, C.-D., Shakir, Y.A., et al. “Could androgens protect middle-aged women from cardiovascular events? A population-based study of Swedish women: The Women’s Health in the Lund Area (WHILA) Study.” Climacteric 10.5 (2007): 386–92.
  41. Berridge, M.J. “Vitamin D cell signalling in health and disease.” Biochem Biophys Res Commun 460.1 (2015): 53–71.
  42. Komisarenko, Y.I., Bobryk, M.I., Sidorova, I.V., Burka, О.А. “Vitamin D: potential clinical decisions in doctor practice.” Reproductive Endocrinology 20 (2014): 105–8.
  43. Komisarenko, Y.I., Bobryk, M.I. “Vitamin D Deficiency and Immune Disorders in Combined Endocrine Pathology.” Front Endocrinol (Lausanne) 9 (2018): 600.
  44. Wehr, E., Pilz, S., Schweighofer, N., et al. “Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome.” Eur J Endocrinol 161.4 (2009): 575–82.
  45. Hassan, N.E., El-Orabi, H.A., Eid, Y.M., Mohammed, N.R. “Effect of 25-hydroxyvitamin D on metabolic parameters and insulin resistance in patients with polycystic ovarian syndrome.” Middle East Fertil Soc J 17.3 (2012): 176–80.
  46. Kim, J.J., Choi, Y.M., Chae, S.J., et al. “Vitamin D deficiency in women with polycystic ovary syndrome.” Clin Exp Reprod Med 41(2) (2014): 80–5.
  47. Li, H.W.R., Brereton, R.E., Anderson, R.A., et al. “Vitamin D deficiency is common and associated with metabolic risk factors in patients with polycystic ovary syndrome.” Metabolism 60.10 (2011): 1475–81.
  48. Yildizhan, R., Kurdoglu, M., Adali, E., et al. “Serum 25-hydroxyvitamin D concentrations in obese and non-obese women with polycystic ovary syndrome.” Arch Gynecol Obstet 280.4 (2009): 559–63.
  49. Velija-Ašimi, Z. “Evaluation of the association of vitamin D deficiency with gonadotropins and sex hormone in obese and non-obese women with polycystic ovary syndrome.” Med Glas (Zenica) 11.1: (2014): 170–6.
  50. Hahn, S., Haselhorst, U., Tan, S., et al. “Low Serum 25-Hydroxyvitamin D Concentrations are Associated with Insulin Resistance and Obesity in Women with Polycystic Ovary Syndrome.” Exp Clin Endocrinol Diabetes 114.10 (2006): 577–83.
  51. Pal, L., Berry, A., Coraluzzi, L., et al. “Therapeutic implications of vitamin D and calcium in overweight women with polycystic ovary syndrome.” Gynecol Endocrinol 28.12 (2012): 965–8.
  52. Marquina, C., Mousa, A., Scragg, R., de Courten, B. “Vitamin D and cardiometabolic disorders: a review of current evidence, genetic determinants and pathomechanisms.” Obes Rev 20.2 (2019): 262–77.
  53. Legro, R.S., Arslanian, S.A., Ehrmann, D.A., et al. “Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline.” J Clin Endocrinol Metab 98.12 (2013): 4565–92.
  54. Conway, G., Dewailly, D., Diamanti-Kandarakis, E., et al. “The polycystic ovary syndrome: a position statement from the European Society of Endocrinology.” Eur J Endocrinol 171.4 (2014): 1–29.
  55. World Health Organization. About diabetes. Geneva. WHO (2013). Available from: [https://www.], last accessed May 16, 2019.
  56. Yang, G., Li, C., Gong, Y., et al. “Assessment of Insulin Resistance in Subjects with Normal Glucose Tolerance, Hyperinsulinemia with Normal Blood Glucose Tolerance, Impaired Glucose Tolerance, and Newly Diagnosed Type 2 Diabetes (Prediabetes Insulin Resistance Research).” J Diabetes Res (2016): 9270768.
  57. Klonoff, D.C., Aron, D., Cohen, R.M., et al. “The Need for Accuracy in Hemoglobin A1c Proficiency Testing: Why the Proposed CLIA Rule of 2019 Is a Step Backward.” J Diabetes Sci Technol 13.3 (2019): 424–7.
  58. Polak, K., Czyzyk, A., Simoncini, T., Meczekalski, B. “New markers of insulin resistance in polycystic ovary syndrome.” J Endocrinol Invest 40.1 (2017): 1–8.
  59. Pfützner, P.A., Standl, E., Hohberg, C., et al. “IRIS II Study: Intact Proinsulin Is Confirmed as a Highly Specific Indicator for Insulin Resistance in a Large Cross-Sectional Study Design.” Diabetes Technology & Therapeutics 7.3 (2005).
  60. Pfützner, A., Pfützner, A.H., Kann, P.H., Burgard, G. “Clinical and Laboratory Evaluation of a New Specific Point-of-Care Test for Intact Proinsulin.” J Diabetes Sci Technol 11.2 (2017): 278–83.
  61. Pfützner, A., Kunt, T., Hohberg, C., et al. “Fasting Intact Proinsulin Is a Highly Specific Predictor of Insulin Resistance in Type 2 Diabetes.” Diabetes Care 27.3 (2004): 682–7.
  62. Røder, M.E. “Hyperproinsulinemia in obesity and in type 2 diabetes and its relation to cardiovascular disease.” Expert Rev Endocrinol Metab 12.4 (2017): 227–39.
  63. Desimone, M.E., Weinstock, R.S. Pancreatic Islet Function Tests. Endotext., Inc. (2000).
  64. Sherwani, S.I., Khan, H.A., Ekhzaimy, A., et al. “Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients.” Biomark Insights 11 (2016): 95–104.
  65. Speiser, P.W., Azziz, R., Baskin, L.S., et al. “Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline.” J Clin Endocrinol Metab 95.9 (2010): 4133–60.
  66. Reznichenko, V.M., Bobryk, M.I., Sidorova, I.V. “Innovative role of evaluation of proinsulin in type 2 diabetes mellitus.” Diabetes. Obesity. Metabolic syndrome 1 (2018): 101–4.



How to Cite

Бурка, О. А., Бобрик, М. І., Резниченко, В. М., & Тутченко, Т. М. (2019). Modern approaches to diagnostics of hyperandrogenism distributed forms in reproductive aged women. REPRODUCTIVE ENDOCRINOLOGY, (47), 35–42.




Most read articles by the same author(s)

1 2 > >>